Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas

D. A. Clayman, S. M. Wolpert, Deborah O Heros

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can be reduced if the BCNU is dissolved in dextrose in water. This article describes the results from 15 patients who received 42 courses of BCNU administered by supraophthalmic internal carotid, middle cerebral, or posterior cerebral artery infusions. None of the patients developed leukoencephalopathy as demonstrated by CT scanning. The average reduction in tumor volume was 36%, and the median survival time from the date of diagnosis was 73 weeks. These values are comparable to those of a previous group of 20 patients treated with infraophthalmic infusions, with the exception that none of the patients in the present group developed retinal damage.

Original languageEnglish
Pages (from-to)767-771
Number of pages5
JournalAmerican Journal of Neuroradiology
Volume10
Issue number4
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Carmustine
Glioma
Retinaldehyde
Posterior Cerebral Artery
Therapeutics
Leukoencephalopathies
Tumor Burden
Glucose
Survival
Water

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas. / Clayman, D. A.; Wolpert, S. M.; Heros, Deborah O.

In: American Journal of Neuroradiology, Vol. 10, No. 4, 01.01.1989, p. 767-771.

Research output: Contribution to journalArticle

Clayman, D. A. ; Wolpert, S. M. ; Heros, Deborah O. / Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas. In: American Journal of Neuroradiology. 1989 ; Vol. 10, No. 4. pp. 767-771.
@article{6b353aa3cab0423fadea8925ee0fc2bd,
title = "Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas",
abstract = "Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can be reduced if the BCNU is dissolved in dextrose in water. This article describes the results from 15 patients who received 42 courses of BCNU administered by supraophthalmic internal carotid, middle cerebral, or posterior cerebral artery infusions. None of the patients developed leukoencephalopathy as demonstrated by CT scanning. The average reduction in tumor volume was 36{\%}, and the median survival time from the date of diagnosis was 73 weeks. These values are comparable to those of a previous group of 20 patients treated with infraophthalmic infusions, with the exception that none of the patients in the present group developed retinal damage.",
author = "Clayman, {D. A.} and Wolpert, {S. M.} and Heros, {Deborah O}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "767--771",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "4",

}

TY - JOUR

T1 - Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas

AU - Clayman, D. A.

AU - Wolpert, S. M.

AU - Heros, Deborah O

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can be reduced if the BCNU is dissolved in dextrose in water. This article describes the results from 15 patients who received 42 courses of BCNU administered by supraophthalmic internal carotid, middle cerebral, or posterior cerebral artery infusions. None of the patients developed leukoencephalopathy as demonstrated by CT scanning. The average reduction in tumor volume was 36%, and the median survival time from the date of diagnosis was 73 weeks. These values are comparable to those of a previous group of 20 patients treated with infraophthalmic infusions, with the exception that none of the patients in the present group developed retinal damage.

AB - Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can be reduced if the BCNU is dissolved in dextrose in water. This article describes the results from 15 patients who received 42 courses of BCNU administered by supraophthalmic internal carotid, middle cerebral, or posterior cerebral artery infusions. None of the patients developed leukoencephalopathy as demonstrated by CT scanning. The average reduction in tumor volume was 36%, and the median survival time from the date of diagnosis was 73 weeks. These values are comparable to those of a previous group of 20 patients treated with infraophthalmic infusions, with the exception that none of the patients in the present group developed retinal damage.

UR - http://www.scopus.com/inward/record.url?scp=0024379362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024379362&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 767

EP - 771

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 4

ER -